Le Lézard
Classified in: Health, Business
Subject: RCN

Sangamo Therapeutics Announces Technology Leadership Changes



RICHMOND, Calif., July 13, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that Michael Holmes, Ph.D., Senior Vice President and Chief Technology Officer, will resign from the Company effective July 20th to pursue an opportunity with a startup biotech company. Edward Rebar, Ph.D., has been named Senior Vice President and Chief Technology Officer, effective immediately.

Sangamo Therapeutics, Inc. (PRNewsfoto/Sangamo Therapeutics, Inc.)

"We wish Michael well in his new endeavor," said Sandy Macrae, CEO of Sangamo. "We are grateful for his contributions to Sangamo over the years and are excited for him as he pursues this ground-floor opportunity at a biotech startup."

Dr. Holmes joined Sangamo in 2001 as a senior scientist and over the years has been promoted to lead many of Sangamo's research programs. Along with Dr. Rebar and other Sangamo scientists, Dr. Holmes made important contributions to the development of zinc finger proteins for therapeutic, research and agricultural applications. He was named Chief Technology Officer earlier in 2018.

Dr. Rebar joined Sangamo in 1998, and over the last 20 years he has led the development of the Company's zinc finger protein platform. He has authored over 60 publications relating to the development of customized DNA binding proteins and nucleases for genome editing.  Prior to joining Sangamo, he was a post-doctoral fellow at the University of California, Berkeley.  Dr. Rebar earned his B.S. in Biochemistry from Rutgers University and his Ph.D. in Biophysics and Structural Biology from MIT.

"I'm very pleased to announce Ed Rebar's promotion to Chief Technology Officer," Macrae said. "During his tenure at Sangamo, Ed has led the development and optimization of our core zinc finger technology. In the field of genome editing he is recognized as a leader and a strong voice for setting very high standards for editing technology being developed for therapeutic use."

About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit the Company's website at www.sangamo.com.

 

SOURCE Sangamo Therapeutics, Inc.


These press releases may also interest you

at 19:30
The "Laboratory Information Management System/LIMS Market by Type, Component (Software, Service), Deployment Model (On-premise, Remote, Cloud), Industry (CRO, CMO, Toxicology, Pharma, Biotech, Chemical, Agriculture, Oil, Gas) - Global Forecast to...

at 18:00
SCOTTSDALE, Ariz., July 18, 2018 /PRNewswire-PRWeb/ -- Dr. Nikesh Seth has stood at the forefront of medical innovation for pain management. He and the physicians at Scottsdale-based Integrated Pain Consultants have were early adopters of...

at 17:54
The U.S. Anti-Doping Agency (USADA) announced today that former UFC Middleweight Champion Anderson Silva's positive test for banned substances in October 2017 was a result of contaminated supplements purchased from a Brazilian compounding pharmacy,...

at 17:50
The Honourable Ginette Petitpas Taylor, Minister of Health, will hold a media availability to highlight the Government of Canada's commitment to seniors. The Minister will be available to answer questions from the media. DateJuly 19, 2018...

at 17:45
The "Personalized Medicine - Scientific and Commercial Aspects" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. This report describes the latest concepts of development of personalized medicine based on...

at 17:16
Pneuma Respiratory, Inc., which has developed PNEUMAHALERtm,, the first breath-activated digital inhaler (BDI), has raised $8.3 million in a Series A financing round. Pneuma Respiratory, Inc. ("Pneuma") has developed the PNEUMAHALERtm Breath...




News published on 13 july 2018 at 16:15 and distributed by: